Bastian Neesgaard
A5037165545- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- HIV Research and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Tuberculosis Research and Epidemiology
- COVID-19 and healthcare impacts
- HIV, Drug Use, Sexual Risk
- Cytomegalovirus and herpesvirus research
- Liver Disease Diagnosis and Treatment
- Esophageal and GI Pathology
- Biochemical and Molecular Research
- Lymphoma Diagnosis and Treatment
- Diagnosis and treatment of tuberculosis
- Blood groups and transfusion
- COVID-19 Clinical Research Studies
- Ultrasound in Clinical Applications
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
University of Copenhagen
2019-2025
Rigshospitalet
2020-2025
Centre of Excellence for Health, Immunity and Infections
2020-2025
University Hospital of Bern
2023
Pomeranian Medical University
2022
Johns Hopkins University
2022
Ministry of Health
2022
Copenhagen University Hospital
2018
University of Missouri
2017
Abstract Objective To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)‐based antiretroviral therapy (ART) versus non‐nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease (PIs) RESPOND consortium cohorts. Methods Eligible were aged ≥18 years who initiated a new three‐drug ART regimen for first time (baseline), did not have hypertension, and had at least two follow‐up blood pressure (BP) measurements....
Mortality among people with human immunodeficiency virus (HIV) declined the introduction of combination antiretroviral therapy. We investigated trends in mortality HIV from 1999 through 2020. Data were collected Collection on Adverse events Anti-HIV Drugs (D:A:D) cohort between January 2015 and International Cohort Consortium Infectious Disease (RESPOND) October 2017 December Age-standardized all-cause cause-specific rates, classified using Coding Causes Death HIV, calculated. Poisson models...
Abstract Background With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases higher diabetes mellitus (DM) risk, we explored the relationships between INSTI/non-INSTI regimens, changes, DM risk. Methods RESPOND participants were included if they had CD4, human immunodeficiency virus (HIV) RNA, ≥2 measurements during follow-up. Those prior excluded. was defined as a random blood glucose ≥11.1 mmol/L, hemoglobin A1c ≥6.5%/48...
Abstract Background There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact different variables RESPOND cohort. Methods included treatment-naive participants aged ≥18 who initiated 3-drug ART, 2014–2020. assessed odds suppression (VS) at weeks 48 and 96 using logistic regression. Viral blips, low-level viremia (LLV), residual (RV),...
Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role low CD4:CD8 ratio elevated CD8 cell counts the cancer remains unclear. We investigated association hazard non-AIDS defining malignancy (NADM), AIDS-defining (ADM) most frequent group cancers ART-treated people with HIV (PWH) a CD4 viral load measurements...
Despite increased integrase strand transfer inhibitor (INSTI) use, limited large-scale, real-life data exists on INSTI uptake and discontinuation.International multicohort collaboration.RESPOND participants starting dolutegravir (DTG), elvitegravir (EVG), or raltegravir (RAL) after January 1, 2012 were included. Predictors of used assessed using multinomial logistic regression. Kaplan-Meier Cox proportional hazards models describe time to factors associated with discontinuation.Overall, 9702...
Assessing whether the previously reported association between abacavir (ABC) and cardiovascular disease (CVD) remained amongst contemporarily treated people with HIV.Multinational cohort collaboration.RESPOND participants were followed from latest of 1 January 2012 or enrolment until first a CVD event (myocardial infarction, stroke, invasive procedure), last follow-up 31 December 2019. Logistic regression examined odds starting ABC by 5-year chronic kidney (CKD) D:A:D risk score. We assessed...
Abstract Background HIV viremia has been considered a cardiovascular disease (CVD) risk factor, but many studies have had insufficient data on potential confounders. We explored the association between and CVD after adjusting for established factors analyzed whether consideration of would improve prediction. Methods Adults from RESPOND were followed first date with available until rigorously defined CVD, loss to follow-up, death, or administrative censoring. associations 6 measures...
Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care HIV, antiretroviral treatment (ART) and virologically suppressed (VS), the aim of monitoring Continuum Care estimate efficacy programmes. We developed an estimation-tool, ESTIHIV, determined minimal required for a random sample, produce representative estimates, specified level precision, people ART VS. For proof concept, 8852 positive persons from seven different countries, follow-up visit during...
Tuberculosis remains the leading cause of death among people with HIV. The aim this study was to describe incidence tuberculosis (TB), explore risk factors and calculate their population attributable fractions (PAF) in HIV across Europe, stratified by region. Longitudinal aged>18 years follow-up from either 1/1/2012, or cohort enrolment, until date TB diagnosis, last visit, death, 31/12/2022. Factors associated TB, particular antiretroviral therapy status smoking, were analysed using...
Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised incidence rates (IRs) from 2006-2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 (31% ART-naïve at baseline) 490,376 total person-years of follow-up (PYFU), were 3763...
Abstract Background Limited data exist that compare clinical outcomes of 2-drug regimens (2DRs) and 3-drug (3DRs) in people living with human immunodeficiency virus. Methods Antiretroviral treatment–experienced individuals the International Cohort Consortium Infectious Diseases (RESPOND) who switched to a new 2DR or 3DR from 1 January 2012–1 October 2018 were included. The incidence events (AIDS, non-AIDS cancer, cardiovascular disease, end-stage liver renal death) was compared between using...
Background: War in Ukraine has forced migration for safety, protection and assistance, including medical care.So far >10 million border crossings to the neighbour countries were registered, with Poland being primary refugee sheltering country over 1.2 Ukrainian refugees registered scheme.HIV disease burden is disproportionately high approximately 0.6% prevalence ∼130 000 antiretroviral (ARV) treated compared ∼0.1% ∼15 people on ARV as of March 2022.Since beginning war 2252 migrants entered...
To assess the use of two-drug antiretroviral regimens (2DR) and virologic immunologic outcomes compared with three-drug (3DR) in EuroSIDA cohort.Multicentre, prospective cohort study.Logistic regression was used to analyse uptake among HIV-positive individuals who started or switched a 2DR those on 3DR. Virologic were assessed on-treatment as proportion controlled viral load (<400 copies/ml), composite modified FDA snapshot endpoint (mFDA), mFDA success defined at 6 months 12 for known load,...
Objectives: People with HIV and extensive antiretroviral exposure may have limited/exhausted treatment options (LExTO) due to resistance, comorbidities, or antiretroviral-related toxicity. Predictors of LExTO were investigated in the RESPOND cohort. Methods: Participants on ART for at least 5 years defined as having when switched two anchor agents one third (any class), a two-drug regimen (excluding rilpivirine dolutegravir/cabotegravir), three nucleoside reverse transcriptase inhibitors....
Objectives To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease (PI/b)-containing non-nucleotide reverse transcriptase (NNRTI)-containing regimens in a real-life setting. Methods Using logistic regression, INSTI use were compared to PI/b or NNRTI treatment 12 months after start switch, for participants the RESPOND cohort consortium. A composite outcome (cTO) was used, defining success as viral load (VL) <200 copies/mL...
Abstract Background Although people with HIV might be at risk of severe outcomes from infection acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; 2019 [COVID‐19]), regional and temporal differences in SARS‐CoV‐2 testing across Europe have not been previously described. Methods We described the proportions testing, positive test results, hospitalizations due to COVID‐19 between 1 January 2020 31 December 2021 EuroSIDA cohort factors associated being tested for ever positive. Results Of...
Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence 25/10
Abstract Spatial resolution in existing chest x-ray (CXR)-based scoring systems for coronavirus disease 2019 (COVID-19) pneumonia is low, and should be increased better representation of anatomy, severity lung involvement. An CXR-based system, the Brixia score, was modified to increase spatial resolution, creating MBrixia score. The score sum, a rule-based quantification CXR on scale 0 3 12 anatomical zones lungs. applied images from COVID-19 patients at single tertiary hospital period May...
Abstract Introduction Data on safety and effectiveness of RPV from the real-world setting as well comparisons with other NNRTIs such efavirenz (EFV) remain scarce. Methods Participants EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann–Whitney U test Chi-square test. A logistic regression model used to compare participants’ characteristics by treatment group. Kaplan–Meier...
Background With the introduction of direct acting antivirals, treatment hepatitis C virus (HCV) in hard-to-reach populations is now feasible. Therefore, new cost-effective and reliable test methods are needed. Determination HCV antibodies HCV-RNA from dried blood spots samples could represent one such method. Here we examined whether anti-HCV be detected—and quantified—from spots, sent by regular mail. We also investigated, if IP-10 determined correlated with fibrosis progression appraised...
Abstract Background Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until earliest first cancer, final follow-up, December 31, 2019. Negative binomial regression was used to assess associations incidence time-updated INSTI exposure, lagged by 6 months. Results Of 29 340 individuals, 74% male, 24% antiretroviral...